Stocks Getting Investor’s Focus: Twitter (NYSE:TWTR), Neonode (NASDAQ:NEON), Valeant Pharmaceuticals Intl (NYSE:VRX), Endocyte (NASDAQ:ECYT), Green Cures & Botanical Distribution (OTCMKTS:GRCU)

Posted by on Jun 19, 2014

Twitter Inc. (NYSE:TWTR) announced that it officially supports animated GIFs, in addition to pictures, videos and regular text. Twitter Inc. (NYSE:TWTR) net profit margin is -93.70% and weekly performance is 9.00%. On last trading day company shares ended up $38.74. Analysts mean target price for the company is $43.73. Twitter Inc. (NYSE:TWTR) distance from 50-day simple moving average (SMA50) is 4.86%.

Neonode Inc. (NASDAQ:NEON) has gone bankrupt twice and is “facing inevitable bankruptcy again,” writes SA author The Pump Stopper in a very critical column.The author calls Neonode’s optical infrared touch technology “obsolete,” “commoditized,” and “the modern touchscreen equivalent of an ‘8-track’ player,” and deems the company to be a weak player even within the IR-touch niche. Neonode, Inc. (NASDAQ:NEON) shares fell -21.95% in last trading session and ended the day on $3.13. NEON gross Margin is 57.10% and its return on assets is -130.70%.Neonode, Inc. (NASDAQ:NEON) quarterly performance is -53.70%.

Valeant Pharmaceuticals Intl Inc. (NYSE:VRX) said it has made a bid for Allergan, the maker of Botox. The cash and stock offer values Allergan Inc. around $53 billion. It expires Aug. 15. Valeant, based in Canada, has teamed up with Bill Ackman’s Pershing Square Capital Management to try to purchase Allergan. The two companies went public with their takeover attempt in April and have increased their offer several times. Allergan, of Irvine, Calif., said the latest offer is still too low. Valeant Pharmaceuticals Intl Inc. (NYSE:VRX) shares moved down -0.37% in last trading session and was closed at $118.43, while trading in range of $117.81 – $120.52. Valeant Pharmaceuticals Intl Inc. (NYSE:VRX) year to date (YTD) performance is 0.88%.

Endocyte, Inc., (NASDAQ:ECYT) announced that it has regained the worldwide rights to vintafolide in all indications from Merck, known as MSD outside the United States and Canada. Following a comprehensive portfolio assessment, Merck, through a subsidiary, has decided that it will no longer pursue development of vintafolide. Endocyte, Inc. (NASDAQ:ECYT) ended the last trading day at $6.64. Company weekly volatility is calculated as 6.48% and price to cash ratio as 2.22.Endocyte, Inc. (NASDAQ:ECYT) showed a negative weekly performance of -2.50%.

Green Cures & Botanical Distribution Inc. (OTCMKTS:GRCU) Chief Executive Officer, Robert Calkin on 9 June provided the following industries overview and a corporate update. Green Cures seeks to become the leading cannabis and botanical industry innovator, by providing the highest quality hempseed oils and cannabis flower topical medicinal and botanical products, as permitted by law. On last trading day company shares ended up $0,0219.


Leave a Reply

Your email address will not be published. Required fields are marked *